Abstract
MicroRNAs are small noncoding RNAs that have emerged as important regulators of many biological and pathological processes, including those relevant to the development of the heart and cardiovascular disease. Several recent studies using genetic models and profiling of microRNAs have established the important role of these novel molecules in a number of conditions of the heart. These studies have led to a flurry of research focussing on the identification of new therapeutic targets for the treatment of cardiac disease, as well as the identification of potential biomarkers for early diagnosis of heart disease. These early reports have stimulated much interest in microRNAs and indeed other non-coding RNAs in the broader context of cardiovascular disease. This work has been further investigated as a result of ease with which the levels of these molecules can be modulated both in vitro but also in animal disease models. Furthermore, a number of studies have specifically looked at the prognostic potential of these microRNAs as biomarkers of cardiovascular disease. This review is focused on highlighting some of the novel aspects of recent research in the area of the development of new therapeutics and better diagnostics for cardiovascular disease.
Keywords: microRNA, cardiovascular disease, biomarkers.
Current Pharmaceutical Design
Title:microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Volume: 20 Issue: 14
Author(s): Shinji Hagiwara, Phillip Kantharidis and Mark E. Cooper
Affiliation:
Keywords: microRNA, cardiovascular disease, biomarkers.
Abstract: MicroRNAs are small noncoding RNAs that have emerged as important regulators of many biological and pathological processes, including those relevant to the development of the heart and cardiovascular disease. Several recent studies using genetic models and profiling of microRNAs have established the important role of these novel molecules in a number of conditions of the heart. These studies have led to a flurry of research focussing on the identification of new therapeutic targets for the treatment of cardiac disease, as well as the identification of potential biomarkers for early diagnosis of heart disease. These early reports have stimulated much interest in microRNAs and indeed other non-coding RNAs in the broader context of cardiovascular disease. This work has been further investigated as a result of ease with which the levels of these molecules can be modulated both in vitro but also in animal disease models. Furthermore, a number of studies have specifically looked at the prognostic potential of these microRNAs as biomarkers of cardiovascular disease. This review is focused on highlighting some of the novel aspects of recent research in the area of the development of new therapeutics and better diagnostics for cardiovascular disease.
Export Options
About this article
Cite this article as:
Hagiwara Shinji, Kantharidis Phillip and Cooper E. Mark, microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990495
DOI https://dx.doi.org/10.2174/13816128113199990495 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart
Current Cardiology Reviews Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design Role of Sympathetic Nerve Activity in Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews Editorial [Hot Topic: Stroke Prevention (Guest Editors: T. Tatlisumak, K. Rantanen and M. Fisher)]
Current Drug Targets mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Insulin Resistance, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cell-Based Therapy to Promote Angiogenesis in the Brain Following Ischemic Damage
Current Vascular Pharmacology Assessment of Coronary Microcirculation with Myocardial Contrast Echocardiography
Current Pharmaceutical Design Current Status of CETP Inhibitors in the Treatment of Hyperlipidemia: An Update
Current Clinical Pharmacology Imidazoline Receptor Agonists in Obesity-Related Hypertension: Therapeutic Targeting of the Sympathetic Nervous System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition The Epidemiology of Cardiovascular Disease in Adults with Type 1 Diabetes
Current Diabetes Reviews Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction
Current Cardiology Reviews Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function
Current Drug Targets Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism CCR2 Antagonists
Current Topics in Medicinal Chemistry Peroxisome Proliferator-Activated Receptor ?? (PPAR??) and Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Hemicellulose from Plant Biomass in Medical and Pharmaceutical Application: A Critical Review
Current Medicinal Chemistry A New Method for Measuring Total Antioxidant Capacity in Urine Using the Iodine Starch Agar Based on Agar diffusion
Current Analytical Chemistry Gender And Susceptibility To Sepsis Following Trauma
Endocrine, Metabolic & Immune Disorders - Drug Targets